Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

551 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
Lasagna A, Mele D, Bergami F, Alaimo D, Dauccia C, Alessio N, Comolli G, Pasi F, Muzzi A, Novelli V, Baldanti F, Pedrazzoli P, Cassaniti I. Lasagna A, et al. Among authors: baldanti f. Hum Vaccin Immunother. 2023 Dec 15;19(3):2288282. doi: 10.1080/21645515.2023.2288282. Epub 2023 Dec 1. Hum Vaccin Immunother. 2023. PMID: 38037900 Free PMC article.
Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.
Gerna G, Piccinini G, Genini E, Percivalle E, Zavattoni M, Lilleri D, Testa L, Comolli G, Maserati R, Baldanti F, Maccario R, Monforte AD, Revello MG. Gerna G, et al. Among authors: baldanti f. J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):320-31. doi: 10.1097/00126334-200112010-00003. J Acquir Immune Defic Syndr. 2001. PMID: 11707667
Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients.
Paolucci S, Baldanti F, Zavattoni M, Comolli G, Labò N, Menzo S, Clementi M, Gerna G. Paolucci S, et al. Among authors: baldanti f. J Antimicrob Chemother. 2003 Jan;51(1):135-9. doi: 10.1093/jac/dkg016. J Antimicrob Chemother. 2003. PMID: 12493798
Monitoring of human cytomegalovirus (HCMV)-specific CD4+ T cell frequency by cytokine flow cytometry as a possible indicator for discontinuation of HCMV secondary prophylaxis in HAART-treated AIDS patients.
Lilleri D, Piccinini G, Genini E, Comolli G, Chiesa A, Tordato F, Sotgiu G, Parisi A, Baldanti F, Revello MG, Gerna G. Lilleri D, et al. Among authors: baldanti f. J Clin Virol. 2004 Apr;29(4):297-307. doi: 10.1016/S1386-6532(03)00214-2. J Clin Virol. 2004. PMID: 15018859
551 results